Canaccord lowered the firm’s price target on Compass Pathways to $50 from $60 and keeps a Buy rating on the shares. The frm said they continue to view the company as significantly undervalued and with the completion of a private placement offering removing a financing overhang, investors can now focus on upcoming Phase 3 data.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on CMPS:
- Rising High: Exclusive talk with psilocybin producer Rose Hill
- Compass prices up to $285M private placement financing
- COMPASS Pathways Announces Up to $285 Million Private Placement Financing Joined by Leading Healthcare Investors
- Rising High: Exclusive talk with cannabis market research firm BDSA
- Here’s What You Missed in Cannabis This Week